Vericel Corp (VCEL) stock
VCELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/30329% above fair value
$58.65+0.77 (+1.33%)
Close on Nov 18, 2026Market cap $3.00BP/E 139.6Yield –
Vericel shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Vericel's shares outstanding was 52M at Jun 30, 2026. For fiscal 2025 it was 52M, up 0.9% from the year before. Over ten years it grew 8.2% a year on average. The highest annual figure on record is 52M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 52M | +0.9% |
| FY2024 | Dec 31, 2024 | 52M | +8.6% |
| FY2023 | Dec 31, 2023 | 48M | +1.0% |
| FY2022 | Dec 31, 2022 | 47M | +1.4% |
| FY2021 | Dec 31, 2021 | 46M | -1.7% |
| FY2020 | Dec 31, 2020 | 47M | +7.0% |
| FY2019 | Dec 31, 2019 | 44M | +9.8% |
| FY2018 | Dec 31, 2018 | 40M | +20.6% |
| FY2017 | Dec 31, 2017 | 33M | +44.4% |
| FY2016 | Dec 31, 2016 | 23M | -2.8% |
| FY2015 | Dec 31, 2015 | 24M | +104.1% |
| FY2014 | Dec 31, 2014 | 12M | +286.0% |
| FY2013 | Dec 31, 2013 | 3M | +46.4% |
| FY2012 | Dec 31, 2012 | 2M | +66.6% |
| FY2010 | Jun 30, 2010 | 1M | +38.3% |
| FY2009 | Jun 30, 2009 | 1M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 52M | +3.9% |
| Q1 FY2026 | Mar 31, 2026 | 51M | +1.7% |
| Q4 FY2025 | Dec 31, 2025 | 58M | -4.9% |
| Q3 FY2025 | Sep 30, 2025 | 52M | +5.8% |
| Q2 FY2025 | Jun 30, 2025 | 50M | +3.5% |
| Q1 FY2025 | Mar 31, 2025 | 50M | +3.7% |
| Q4 FY2024 | Dec 31, 2024 | 61M | +27.3% |
| Q3 FY2024 | Sep 30, 2024 | 49M | +3.0% |
| Q2 FY2024 | Jun 30, 2024 | 49M | +2.3% |
| Q1 FY2024 | Mar 31, 2024 | 48M | +1.6% |
| Q4 FY2023 | Dec 31, 2023 | 48M | +1.1% |
| Q3 FY2023 | Sep 30, 2023 | 48M | +1.0% |
| Q2 FY2023 | Jun 30, 2023 | 48M | +1.0% |
| Q1 FY2023 | Mar 31, 2023 | 47M | +0.9% |
| Q4 FY2022 | Dec 31, 2022 | 47M | +0.9% |
| Q3 FY2022 | Sep 30, 2022 | 47M | +1.1% |
| Q2 FY2022 | Jun 30, 2022 | 47M | +1.5% |
| Q1 FY2022 | Mar 31, 2022 | 47M | +2.2% |
| Q4 FY2021 | Dec 31, 2021 | 47M | -13.0% |
| Q3 FY2021 | Sep 30, 2021 | 47M | -1.4% |
| Q2 FY2021 | Jun 30, 2021 | 46M | +2.8% |
| Q1 FY2021 | Mar 31, 2021 | 46M | +2.4% |
| Q4 FY2020 | Dec 31, 2020 | 54M | +20.1% |
| Q3 FY2020 | Sep 30, 2020 | 47M | +1.4% |
| Q2 FY2020 | Jun 30, 2020 | 45M | +2.7% |
| Q1 FY2020 | Mar 31, 2020 | 45M | +2.7% |
| Q4 FY2019 | Dec 31, 2019 | 45M | +3.0% |
| Q3 FY2019 | Sep 30, 2019 | 47M | +8.7% |
| Q2 FY2019 | Jun 30, 2019 | 44M | +14.6% |
| Q1 FY2019 | Mar 31, 2019 | 44M | +21.0% |
| Q4 FY2018 | Dec 31, 2018 | 43M | +24.0% |
| Q3 FY2018 | Sep 30, 2018 | 43M | +27.5% |
| Q2 FY2018 | Jun 30, 2018 | 38M | +17.0% |
| Q1 FY2018 | Mar 31, 2018 | 36M | +13.3% |
| Q4 FY2017 | Dec 31, 2017 | 35M | +44.1% |
| Q3 FY2017 | Sep 30, 2017 | 34M | +48.0% |
| Q2 FY2017 | Jun 30, 2017 | 33M | – |
| Q1 FY2017 | Mar 31, 2017 | 32M | – |
| Q4 FY2016 | Dec 31, 2016 | 24M | – |
| Q3 FY2016 | Sep 30, 2016 | 23M | – |
See a number that looks wrong?